DV
Dividend Vision

IVA — Inventiva Sa

Inventiva Sa (IVA)

Total return is -65.7% over the past 6.1 years, 231.1 points behind SPY at 165.4%. Its deepest 1-year drawdown was 52.3%.

Inventiva S.A. is a clinical-stage biopharmaceutical company developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases, with its lead candidate Lanifibranor currently in Phase 3 clinical trials. The company does not currently distribute dividends. This security is focused on drug development and clinical advancement rather than current income generation, appealing primarily to investors with interest in early-stage biotech ventures.

IVA key facts

Asset type
Stock
Asset class
Equity
Inception date
07/10/2020
Last close
$4.60
Market cap
$1,042,914,176
Average volume
573800.0
Beta
0.892
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.07